Home > Insider Trading > Filing (0000899243-18-027481)

Filing Details

Accession Number:: 0000899243-18-027481
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-10-25 18:28:40
Reporting Period:: 2018-10-23

Accepted Time:: 2018-10-25 18:28:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1664106	Logicbio Therapeutics Inc.	LOGC	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	Yes	No
1682090	Orbimed Israel Gp Ii, L.p.	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	Yes	No
1682093	Ltd Ii Israel Advisors Orbimed	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	Yes	No
1682115	Orbimed Capital Gp Vi Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-10-23	2,997,760	$0.00	2,997,760	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2018-10-23	2,279,023	$0.00	5,276,783	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2018-10-23	490,000	$10.00	5,766,783	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2018-10-23	700,000	$10.00	6,466,783	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2018-10-23	2,678,571	$0.00	1,402,444	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-10-23	3,046,943	$0.00	1,595,316	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-10-23	4,352,775	$0.00	2,279,023	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	No	4	C	Indirect
2,279,023	No	4	C	Indirect
0	No	4	C	Indirect

Footnotes

The total represents shares received upon conversion of Series A and Series B Convertible Preferred Stock.
Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock.
The reportable securities are owned directly by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OIP GP") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Limited") is the managing member of OIP GP. By virtue of such relationships, OIP GP and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Limited.
The reportable securities are owned directly by OrbiMed Private Investments VI ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VI and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein.
This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, OIP GP and OrbiMed Limited. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.